Pharma Firms

The company has registered 10% growth in revenues at Rs 4,431.8 cr for the quarter under review from Rs 4,016.6 cr in the year-ago period

Export growth started declining in February and turned negative in March, at -23.24 per cent

Over 133 million shares, or 5.7% of the paid-up capital, are being offered for Rs 1,850-1,950 to investors through a special block window

8 Malaysians caught trying to leave India

The matter will come up again in court on Monday

The expansion of WBA and TCS strategic partnership is based on WBA's review of its IT operating model and vendor landscape

There is a plan to identify a list of essential medicines, including antibiotics, painkillers, etc, which the company may supply to the Ayushman Bharat-empanelled hospitals.

Ogivri will be launched at a competitive discount for customers to help ensure access and increase treatment options for patients

The Street is cautious given multiple challenges in core markets of US and India

The companies' combined net profit declined by 10.1 per cent yoy during June '19 quarter against 26.2 per cent yoy growth a year ago

In India, the company said it will focus on therapeutic segments like diabetes, dermatology, cardiology and women's health

According to Edelweiss Securities, pharma sales to grow by 17 per cent YoY as US sales are expected to grow by 21 per cent YoY

The BSE Healthcare Index has fallen 10 per cent in the last one year

Top 10 brands (of a company) account for more than 20 per cent of their domestic revenue in the case of most, analysts said

Impact of an escalation of the observations will hit their profit estimates over the next couple of years

44 states have alleged the drugmakers of price fixing

This decline was primarily for two reasons. One, commoditisation of generics led to price erosion. Two, investments increased in both R&D and in expansion

Around 17 per cent of the Rs 1.2-trillion domestic pharma market is currently under price control

Easing of pricing pressures, launch of limited competition drugs in the US, weak rupee are key triggers

The government is also mooting a cooperative manufacturing model for small units